Virios Therapeutics Inc. (NASDAQ:VIRI) shares traded -14.32% lower at $0.35 on Wall Street last session.
VIRI stock price is now 15.71% away from the 50-day moving average and -86.66% away from the 200-day moving average. The market capitalization of the company currently stands at $6.31M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
In other news, Whitley Richard James, Director sold 1,800 shares of the company’s stock on Dec 08. The stock was sold for $466 at an average price of $0.26. Upon completion of the transaction, the Director now directly owns 700 shares in the company, valued at $245.0. An SEC document containing details of the transaction can be found on the SEC’s website. On May 23, CHIEF EXECUTIVE OFFICER Duncan Gregory Scott bought 7,500 shares of the business’s stock. A total of $33,900 was incurred on buying the stock at an average price of $4.52. This leaves the insider owning 32,461 shares of the company worth $11361.35. Insiders disposed of 1,800 shares of company stock worth roughly $630.0 over the past 1 year. A total of 11.44% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in VIRI stock. A new stake in Virios Therapeutics Inc. shares was purchased by ERGOTELES LLC during the first quarter worth $11,000. CETERA INVESTMENT ADVISERS invested $6,000 in shares of VIRI during the first quarter. In the first quarter, CETERA ADVISOR NETWORKS LLC acquired a new stake in Virios Therapeutics Inc. valued at approximately $5,000. URBAN WEALTH MANAGEMENT, LLC acquired a new stake in VIRI for approximately $1,000. In total, there are 30 active investors with 17.00% ownership of the company’s stock.
Virios Therapeutics Inc. (NASDAQ: VIRI) opened at $0.3900 on Tuesday. During the past 12 months, Virios Therapeutics Inc. has had a low of $0.22 and a high of $9.11. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 6.60, and a quick ratio of 6.60. The fifty day moving average price for VIRI is $0.2999 and a two-hundred day moving average price translates $2.6148 for the stock.
The latest earnings results from Virios Therapeutics Inc. (NASDAQ: VIRI) was released for Sep, 2022.
Virios Therapeutics Inc.(VIRI) Company Profile
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company’s lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.
Leave a Reply